Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.6% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment reporting

Analytics

Phase 2
3(75.0%)
Phase 3
1(25.0%)
4Total
Phase 2(3)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01410383Phase 3Terminated

Efficacy and Safety Study of Eprotirome in HeFH Patients Who Are on Optimal Standard of Care

Role: lead

NCT00593047Phase 2Completed

LDL-Cholesterol Lowering Effect of KB2115 as Add on to Statin

Role: lead

NCT00677248Phase 2Completed

LDL-Cholesterol Lowering Effect of KB2115 as Add on to Ezetimibe

Role: lead

NCT00776321Phase 2Completed

Eprotirome for the Treatment of Dyslipidemia, Efficacy and Safety 12-Week, Phase ii Study to Assess the Safety and Efficacy of KB2115 in Patients With Primary Hypercholesterolemia

Role: lead

All 4 trials loaded